合作伙伴征集：2025全球手术机器人大会 报名：首届全球眼科大会 | 展位有限 报名：首届全球心血管大会 | 奖项评选 报名：首届全球骨科大会 | 奖项评选 2025年2月27日， 澳华内镜 发布了2024年度业绩快报公告。 # 财务数据 财务状况 营业收入 ：74,855.55万元，同比增长10.39%。 营业利润 ：702.46万元，同比下降87.07%。 利润总额 ：640.72万元，同比下降88.12%。 归属于母公司所有者的净利润 ：2,132.18万元，同比下降63.15%。 归属于母公司所有者的扣除非经常性损益的净利润 ：-699.79万元，同比下降幅度较大。 基本每股收益 ：0.16元，同比下降62.79%。 加权平均净资产收益率 ：1.55%，同比下降2.82个百分点。 总资产 ：174,834.96万元，较期初增长9.61%。 归属于母公司的所有者权益 ：136,620.03万元，较期初减少1.00%。 每股净资产 ：10.15元，较期初下降1.46%。 | 项目 | 本报告期 | 上年同期 | 增减变动幅度(%) | | --- | --- | --- | --- | | 营业总收入 | ...

Financial Performance - Total revenue for 2024 reached RMB 748.56 million, a year-on-year increase of 10.39%[3] - Net profit attributable to shareholders of the parent company was RMB 21.32 million, a decrease of 63.15% compared to the previous year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB -6.99 million, indicating a significant decline[3] - Basic earnings per share decreased by 62.79% to RMB 0.16[3] Assets and Equity - The company's total assets increased by 9.61% to RMB 1,748.35 million at the end of the reporting period[4] - The company's equity attributable to shareholders decreased by 1.00% to RMB 1,366.20 million[4] Market and Operational Challenges - The company faced limited domestic revenue growth due to a decrease in procurement activities in the domestic terminal market[5] - The company anticipates challenges in meeting performance targets set in previous stock incentive plans, impacting financial results[5] Investment and Growth Strategies - The company expanded its overseas marketing network, leading to revenue growth in international markets[5] - Increased investment in new technology and product development resulted in higher sales, management, and R&D expenses, outpacing revenue growth[5]

证券代码：688212 证券简称：澳华内镜 公告编号：2025-013 上海澳华内镜股份有限公司 关于以集中竞价交易方式首次回购公司股份的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、 回购股份的基本情况 上海澳华内镜股份有限公司（以下简称"公司"）于 2025 年 1 月 3 日召开了 第二届董事会第十六次会议审议通过了《关于以集中竞价交易方式回购公司股份 方案的议案》，同意公司以公司自有资金及中信银行股份有限公司上海分行提供的 股票回购专项贷款通过上海证券交易所交易系统以集中竞价交易方式回购公司股 份，所回购的股份将在未来适宜时机全部用于员工持股计划或股权激励。本次回 购股份的资金总额不低于人民币 10,000 万元（含），不超过人民币 20,000 万元（含）， 回购股份价格不超过人民币 45.00 元/股（含），回购股份期限为自董事会审议通 过回购股份方案之日起的 12 个月内。具体内容详见公司分别于 2025 年 1 月 6 日、 2025 年 1 月 9 日在上海证券交易所网站（www.sse.com. ...

上海澳华内镜股份有限公司（以下简称"公司"）于近日收到软件产品增值税即征 即退退税款人民币817.36万元，均属于与收益相关的政府补助款项。 二、政府补助的类型及对公司的影响 公司根据《企业会计准则第16号——政府补助》等有关规定，确认上述事项并划分 补助类型。上述政府补助未经审计，具体的会计处理以及对公司损益的影响情况最终以 审计机构年度审计确认后的结果为准，敬请广大投资者注意投资风险。 证券代码：688212 证券简称：澳华内镜 公告编号：2025-011 上海澳华内镜股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、获得补助的基本情况 特此公告。 上海澳华内镜股份有限公司董事会 2025年2月15日 ...

证券代码：688212 证券简称：澳华内镜 公告编号：2025-010 上海澳华内镜股份有限公司 股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 股东持股的基本情况 截止本公告披露日，上海澳华内镜股份有限公司（以下简称"公司"）相关 股东持股情况如下： 苏州君联欣康创业投资合伙企业（有限合伙）（以下简称"君联欣康"）持有 公司股份 2,641,371 股，约占公司总股本的 1.96%。高燊有限公司（以下简称"高 燊"）持有公司股份 3,977,872 股，占公司总股本的 2.96%。君联欣康与高燊构 成一致行动人关系，合计持有公司股份 6,619,243 股，占公司总股本的 4.92%。 减持计划的主要内容 君联欣康和高燊拟通过集中竞价、大宗交易方式减持公司股份，合计减持不 超过 4,037,610 股，合计减持比例不超过公司总股本的 3.00%。其中，通过集中 竞价交易方式减持股份不超过公司股份总数的 1%，自本公告披露之日起 3 个交 易日后的 3 个月内进行；通过大宗 ...

| 回购方案首次披露日 | 2025/1/6，由董事会提议 | | | --- | --- | --- | | 回购方案实施期限 | 待董事会审议通过后 12 个月 | | | 预计回购金额 | 10,000 万元 | 万元~20,000 | | 回购用途 | √用于员工持股计划或股权激励 | □减少注册资本 | | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | | 累计已回购股数 | 0.00 | 万股 | | 累计已回购股数占总股本比 | 0.00% | | | 例 | | | | 累计已回购金额 | 0.00 | 万元 | | 实际回购价格区间 | 0.00 元/股 | 元/股~0.00 | 一、 回购股份的基本情况 证券代码：688212 证券简称：澳华内镜 公告编号：2025-009 上海澳华内镜股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 上海澳华内镜股份有限公司（以下简称"公司"）于 2025 年 1 月 3 日召开了 第二届董 ...

Revenue Forecast - The company expects 2024 annual revenue to be between 730.50 million and 754.36 million CNY, an increase of 52.42 million to 76.28 million CNY, representing a year-on-year growth of 7.73% to 11.25%[4]. - The previous year's revenue was 678.08 million CNY, with a net profit of 57.85 million CNY and a net profit after deducting non-recurring gains and losses of 44.49 million CNY[6]. - The increase in overseas market access and business expansion contributed to revenue growth, while domestic business revenue growth was limited due to a decrease in procurement activities[8]. Profit Forecast - The projected net profit attributable to shareholders for 2024 is expected to be between 15.73 million and 23.38 million CNY, a decrease of 34.47 million to 42.12 million CNY, reflecting a year-on-year decline of 59.59% to 72.81%[4]. - The company anticipates a net profit attributable to shareholders after deducting non-recurring gains and losses to be between -12.74 million and -5.09 million CNY for 2024[4]. - Non-recurring gains and losses are expected to impact the net profit attributable to shareholders by approximately 28.47 million CNY, primarily from government subsidies and investment income[8]. Marketing and Expenses - The company has been enhancing its marketing system and brand influence, leading to increased sales, management, and R&D expenses, which grew faster than revenue[8]. Uncertainties and Forecast Validity - The company has not identified any significant uncertainties affecting the accuracy of this earnings forecast[9]. - The forecast data is preliminary and subject to change pending the audited annual report for 2024[10].

Investment Rating - The report initiates coverage with a "Buy" rating for the company [4]. Core Views - The company is a leading domestic flexible endoscope manufacturer, with a well-established product line that supports steady revenue growth. The flagship product AQ-300 targets the high-end market, while other models cater to mid and grassroots markets. The company has achieved a revenue CAGR of 31.66% from 2017 to 2023, driven by market demand recovery and increased sales of mid-to-high-end products [1][2][3]. Summary by Sections Company Overview - The company has been focused on the endoscope field for thirty years, with products widely used in various clinical departments. It has developed a comprehensive product line to meet diverse clinical needs, including the AQ-300, AQ-200, and other models for different market segments [1][2]. Market Potential - The flexible endoscope market in China is dominated by imported brands, with a market size of 7.6 billion yuan in 2022. The leading brands are Olympus and Fujifilm, holding 60.40% and 14.00% market shares, respectively. The company, along with other domestic manufacturers, has significant potential for market share growth due to low domestic production rates and increasing demand for local alternatives [2][3]. Product Development and Innovation - The company has a strong focus on R&D, with a CAGR of 45.92% in R&D expenses from 2017 to 2023. It launched the first domestic 4K ultra-high-definition endoscope in 2022 and plans to introduce several new products in 2024, enhancing its product matrix and competitive edge in high-end markets [3][4]. Marketing and Global Expansion - The company has established a global marketing and service system, with 15 marketing subsidiaries and 34 service points as of mid-2024. It is actively pursuing overseas market access, with 0.68 billion yuan in overseas revenue in 2024H1, accounting for 19.2% of total revenue. The AQ-300 has received CE certification, which is expected to boost overseas sales [4][5]. Financial Forecast and Valuation - The company is projected to achieve revenues of 753 million yuan, 950 million yuan, and 1.189 billion yuan for 2024, 2025, and 2026, respectively, with year-on-year growth rates of 11.1%, 26.1%, and 25.2%. The net profit attributable to the parent company is expected to be 50 million yuan, 80 million yuan, and 115 million yuan for the same years, with growth rates of -13.9%, 60.3%, and 43.8% [4][5].

二、公司前十大无限售条件股东持股信息 | 序号 | | 股东名称 | 持股数量（股） | 占总股本比例（%） | | --- | --- | --- | --- | --- | | 1 | 顾小舟 | | 21,740,500 | 16.15 | 证券代码：688212 证券简称：澳华内镜 公告编号：2025-006 上海澳华内镜股份有限公司 关于回购股份事项前十大股东和前十大无限售条件股东 持股信息的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海澳华内镜股份有限公司（以下简称"公司"）于2025年1月3日以现场与通讯相 结合的方式召开了第二届董事会第十六次会议，审议通过了《关于以集中竞价交易方式 回购公司股份方案的议案》，具体详见公司于2025年1月6日披露于上海证券交易所网站 （www.sse.com.cn）的《关于以集中竞价交易方式回购股份方案的公告》（公告编号： 2025-001）。根据《上海证券交易所上市公司自律监管指引第7号——回购股份》等相关 规定，现将董事会公告回购股份决议的前一个交易日（即20 ...

关于以集中竞价交易方式回购股份的回购报告书 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 ● 回购股份金额：不低于人民币 10,000 万元（含），不超过人民币 20,000 万 元（含）； ● 回购股份资金来源：公司自有资金及中信银行股份有限公司上海分行提供 的股票回购专项贷款。公司已取得中信银行股份有限公司上海分行出具的《贷款承 诺函》，具体贷款事宜将以双方签订的贷款合同为准； 证券代码：688212 证券简称：澳华内镜 公告编号：2025-007 上海澳华内镜股份有限公司 重要内容提示： ● 回购股份用途：员工持股计划或股权激励计划； ● 回购股份价格：不超过人民币 45.00 元/股，该价格未超过公司董事会审议 通过相关决议前 30 个交易日公司股票交易均价的 150%； ● 回购股份方式：集中竞价交易方式； 2024 年 12 月 3 日，公司在上海证券交易所网站（www.sse.com.cn）披露了 《上海澳华内镜股份有限公司持股 5%以上股东减持股份计划公告》（公告编号： 2024-052），公司实际控制人 ...